glp 1 agonists and depression Frontiers GLP-1 Agonists In Obesity
Description
Int J Environ Res Public Health
Br J Clin Pharmacol (2018) 84(10):232535
Boyle, J
Experiments indicate that it acts through the BMP2/Smad/RUNX2 pathway [21] and long intergenic non-coding RNA 968 (LINC00968)/micro-RNA-3658 (miR-3658)/RUNX2 pathway [27]
Amylin: pharmacology, physiology, and clinical potential
Patients may experience side effects such as gastrointestinal discomfort, and certain populations, such as those with pancreatitis or severe gastrointestinal disorders, may not be suitable candidates
